DE69921804D1 - Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten - Google Patents

Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten

Info

Publication number
DE69921804D1
DE69921804D1 DE69921804T DE69921804T DE69921804D1 DE 69921804 D1 DE69921804 D1 DE 69921804D1 DE 69921804 T DE69921804 T DE 69921804T DE 69921804 T DE69921804 T DE 69921804T DE 69921804 D1 DE69921804 D1 DE 69921804D1
Authority
DE
Germany
Prior art keywords
cytokin
treating
mediated diseases
benzamide derivatives
6alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69921804T
Other languages
English (en)
Other versions
DE69921804T2 (de
Inventor
Sutherland Brown
Robert Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810356.7A external-priority patent/GB9810356D0/en
Priority claimed from GBGB9905970.1A external-priority patent/GB9905970D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69921804D1 publication Critical patent/DE69921804D1/de
Application granted granted Critical
Publication of DE69921804T2 publication Critical patent/DE69921804T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69921804T 1998-05-15 1999-05-11 Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten Expired - Fee Related DE69921804T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9810356 1998-05-15
GBGB9810356.7A GB9810356D0 (en) 1998-05-15 1998-05-15 Amide derivatives
GB9905970 1999-03-17
GBGB9905970.1A GB9905970D0 (en) 1999-03-17 1999-03-17 Amide derivatives
PCT/GB1999/001491 WO1999059960A1 (en) 1998-05-15 1999-05-11 Benzamide derivatives for the treatment of diseases mediated by cytokines

Publications (2)

Publication Number Publication Date
DE69921804D1 true DE69921804D1 (de) 2004-12-16
DE69921804T2 DE69921804T2 (de) 2005-10-27

Family

ID=26313677

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921804T Expired - Fee Related DE69921804T2 (de) 1998-05-15 1999-05-11 Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten

Country Status (23)

Country Link
US (1) US6465455B1 (de)
EP (1) EP1077930B1 (de)
JP (1) JP2003505337A (de)
KR (1) KR100628284B1 (de)
CN (1) CN1188389C (de)
AT (1) ATE282023T1 (de)
AU (1) AU748397B2 (de)
BR (1) BR9910467A (de)
CA (1) CA2328699A1 (de)
DE (1) DE69921804T2 (de)
ES (1) ES2230853T3 (de)
HK (1) HK1033753A1 (de)
HU (1) HUP0102367A3 (de)
ID (1) ID27285A (de)
IL (1) IL139710A (de)
NO (1) NO20005766L (de)
NZ (1) NZ507143A (de)
PL (1) PL197181B1 (de)
PT (1) PT1077930E (de)
RU (1) RU2205823C2 (de)
SK (1) SK286247B6 (de)
TR (1) TR200003355T2 (de)
WO (1) WO1999059960A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
CN1271279A (zh) 1997-09-23 2000-10-25 普尼卡有限公司 用于治疗细胞因子介导性疾病的酰胺类衍生物
AU749293B2 (en) 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
HUP0102367A3 (en) 1998-05-15 2002-11-28 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
RU2216541C2 (ru) 1998-08-04 2003-11-20 Астразенека Аб Производные бензамида, способ их получения и фармацевтическая композиция на их основе
EP1112070B1 (de) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Neue substituierte triazolverbindungen
RU2219171C2 (ru) 1998-09-25 2003-12-20 Астразенека Аб Производные амида, способ их получения и фармацевтическая композиция на их основе
CA2361819A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
KR100757282B1 (ko) 1999-03-17 2007-09-11 아스트라제네카 아베 아미드 유도체
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
ATE553758T1 (de) * 2000-12-18 2012-05-15 Inst Med Molecular Design Inc Hemmer für die produktion und freisetzung entzündlicher zytokine
EP1389203B8 (de) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analoga von thalidomid als angiogeneseinhibitoren
TW200410675A (en) * 2002-06-10 2004-07-01 Inst Med Molecular Design Inc An NF-κB activation inhibitor
WO2004004703A1 (ja) * 2002-07-04 2004-01-15 Mitsui Chemicals, Inc. メタフェニレンジアミン誘導体
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
SG133603A1 (en) 2003-09-17 2007-07-30 Us Gov Health & Human Serv Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2629814C (en) * 2005-11-14 2013-12-31 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
AU2007238785B2 (en) 2006-04-13 2013-02-07 Agnieszka Ambrozak Tetrahalogenated compounds useful as inhibitors of angiogenesis
US7671058B2 (en) * 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN104326937B (zh) * 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
US1909960A (en) 1929-08-06 1933-05-23 Du Pont Intermediate for azo dyes
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4524168A (en) 1981-11-18 1985-06-18 Ciba-Geigy Corporation Process for the mass coloration of polymers
US4749729A (en) 1984-06-21 1988-06-07 American Cyanamid Company Epoxy resin compositions curable above 160 F. and below 250 F.
WO1993004170A1 (en) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
EP0871444A4 (de) 1995-08-10 1999-01-13 Merck & Co Inc 2,5 substituierte aryl pyrrol, dieses enthaltende zusammensetzungen und dessen verwendung
USRE39088E1 (en) * 1995-08-22 2006-05-02 Japan Tobacco, Inc. Amide compounds and use of the same
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP2001506230A (ja) * 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
CN1271279A (zh) * 1997-09-23 2000-10-25 普尼卡有限公司 用于治疗细胞因子介导性疾病的酰胺类衍生物
GB9809347D0 (en) 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
AU749293B2 (en) 1998-05-15 2002-06-20 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
HUP0102367A3 (en) 1998-05-15 2002-11-28 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
RU2216541C2 (ru) 1998-08-04 2003-11-20 Астразенека Аб Производные бензамида, способ их получения и фармацевтическая композиция на их основе
RU2219171C2 (ru) 1998-09-25 2003-12-20 Астразенека Аб Производные амида, способ их получения и фармацевтическая композиция на их основе
WO2000020402A1 (en) 1998-10-01 2000-04-13 Astrazeneca Ab Chemical compounds
CA2361819A1 (en) 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
KR100757282B1 (ko) 1999-03-17 2007-09-11 아스트라제네카 아베 아미드 유도체
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
WO1999059960A1 (en) 1999-11-25
HUP0102367A2 (hu) 2001-10-28
SK286247B6 (sk) 2008-06-06
NO20005766L (no) 2001-01-12
PL197181B1 (pl) 2008-03-31
CN1359371A (zh) 2002-07-17
CA2328699A1 (en) 1999-11-25
SK17172000A3 (sk) 2001-04-09
HK1033753A1 (en) 2001-09-21
NZ507143A (en) 2003-08-29
HUP0102367A3 (en) 2002-11-28
PT1077930E (pt) 2005-03-31
EP1077930A1 (de) 2001-02-28
KR20010043547A (ko) 2001-05-25
TR200003355T2 (tr) 2001-03-21
AU3839299A (en) 1999-12-06
KR100628284B1 (ko) 2006-09-27
IL139710A (en) 2005-07-25
ID27285A (id) 2001-03-22
JP2003505337A (ja) 2003-02-12
ES2230853T3 (es) 2005-05-01
ATE282023T1 (de) 2004-11-15
AU748397B2 (en) 2002-06-06
RU2205823C2 (ru) 2003-06-10
US6465455B1 (en) 2002-10-15
BR9910467A (pt) 2001-01-09
IL139710A0 (en) 2002-02-10
CN1188389C (zh) 2005-02-09
NO20005766D0 (no) 2000-11-14
DE69921804T2 (de) 2005-10-27
EP1077930B1 (de) 2004-11-10
PL344185A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
DE69921804D1 (de) Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten
DE69810134T2 (de) Amide derivativen zur behandlung von durch cytokinen vermittelten krankheiten
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
ES2054020T3 (es) Compuestos biologicamente activos.
NO992336L (no) Raf-kinase-inhibitorer
MY142177A (en) Benzamide derivatives useful as histone deacetylase inhibitors
NZ509318A (en) Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE69413118T2 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
DE69218816T2 (de) N-acetyl-cysteine Derivate enthaltende pharmazeutische Zusammensetzung zur Behandlung von Katarakt
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE3880304D1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
RU95117692A (ru) Щелочные соли амидов оротовой кислоты и аминокислот, обладающие гипертензивной активностью

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee